Between August 7 and 9, 2014, a total of 69 new cases of Ebola virus disease (laboratory-confirmed, probable, and suspect cases) as well as 52 deaths were reported from Guinea, Liberia, Nigeria, and Sierra Leone.
The recent treatment with an experimental medicine of two healthcare workers who were infected with EVD has raised important questions about whether medicines or treatments that have never been tested or shown to be safe in humans should be used in this outbreak. Currently, quantities of the medicine are limited, which also raises questions about who should receive the treatment.
On Aug. 11, 2014, the World Health Organization (WHO) convened a panel of medical ethicists, scientific experts and lay persons from the affected countries to assess the role of experimental therapies in the Ebola outbreak response.
Two issues were considered:
1. Is it ethical to use unregistered interventions with unknown adverse effects for possible treatment or prophylaxis? If it is, what criteria and conditions need to be satisfied before they can be used?
2. If it is ethical to use these unregistered interventions in the current circumstances, then what criteria should guide the choice of an intervention and who should receive priority for treatment or prevention?
Disease update: New cases and deaths attributable to EVD continue to be reported by the Ministries of Health in Guinea, Liberia, Nigeria, and Sierra Leone. Between August 7 and 9, 2014, 69 new cases (laboratory-confirmed, probable, and suspect cases) of EVD and 52 deaths were reported from the four countries as follows: Guinea, 11 new cases and 6 deaths; Liberia, 45 new cases and 29 deaths; Nigeria, 0 new cases and 0 deaths; and Sierra Leone, 13 new cases and 17 deaths.
Source: WHO
The Key to Sterile Processing Success: Leadership Engagement and Team Collaboration
January 24th 2025Effective sterile processing leadership requires active engagement, clear communication, and a transformational approach to foster collaboration, accountability, and quality in infection prevention and surgical instrument management.
Evaluating Automated Dispensing Systems for Disinfectants in Hospitals
January 23rd 2025Hospitals rely on automated disinfectant dispensers, but a study led by Curtis Donskey, MD, found inconsistent dilution levels, with some dispensers releasing only water. Improved monitoring and design modifications are essential.
Alcohol-Based Antiseptics Show Promise for Nasal Decolonization and SSI Prevention
January 23rd 2025A meta-analysis found alcohol-based antiseptics significantly reduce Staphylococcus aureus-related surgical site infections (SSIs), demonstrating efficacy comparable to mupirocin and iodophor, supporting their expanded use in infection prevention strategies.
ASRA Pain Medicine Releases Groundbreaking Infection Control Guidelines for Pain Management
January 22nd 2025The American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) released comprehensive infection control guidelines for pain procedures, emphasizing prevention, early recognition, multidisciplinary collaboration, and judicious antibiotic use to enhance patient safety and healthcare outcomes.